Literature DB >> 15270893

The effect of haematopoietic stem cell transplant on papules with 'pebbly' appearance in Hunter's syndrome.

K Ito1, T Ochiai, H Suzuki, M Chin, H Shichino, H Mugishima.   

Abstract

BACKGROUND: Hunter's syndrome is associated with several cutaneous findings. For instance, papules with 'pebbly' appearance are a specific marker for the disease. However, it remains uncertain whether they disappear after haematopoietic stem cell transplant (HSCT).
OBJECTIVES: To investigate the papules with 'pebbly' appearance before and after HSCT in infants with Hunter's syndrome, and to clarify the effect of HSCT on papules. PATIENTS: We observed five Japanese boys with Hunter's syndrome who had received HSCT at 4-11 years of age.
RESULTS: The post-HSCT physical examinations revealed that papules disappeared completely within 35 days after the transplant with progressive reduction of cutaneous tightness in all the patients. Histochemical findings showed that papules contained a large amount of hyaluronic acid in the extracellular materials of the dermis and sulphated acid mucopolysaccharides in dermal fibroblasts before HSCT.
CONCLUSIONS: These results suggest that papules with a 'pebbly' appearance fade away through the digestion of a large amount of hyaluronic acid in cutaneous tissues by normal tissue histiocytes or enzymes of donor origin at an early stage after HSCT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270893     DOI: 10.1111/j.1365-2133.2004.05944.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Molecular analysis of the novel IDS allele in a Thai family with mucopolysaccharidosis type II: The c.928C>T (p.Gln310*) transcript is sensitive to nonsense-mediated mRNA decay.

Authors:  Lukana Ngiwsara; Kitiwan Rojnueangnit; Duangrurdee Wattanasirichaigoon; Thipwimol Tim-Aroon; Phannee Sawangareetrakul; Voraratt Champattanachai; James R Ketudat-Cairns; Jisnuson Svasti
Journal:  Exp Ther Med       Date:  2017-04-05       Impact factor: 2.447

2.  Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II.

Authors:  Kentaro Yokoi; Kazumasa Akiyama; Eiko Kaneshiro; Takashi Higuchi; Yohta Shimada; Hiroshi Kobayashi; Masaharu Akiyama; Makoto Otsu; Hiromitsu Nakauchi; Toya Ohashi; Hiroyuki Ida
Journal:  J Inherit Metab Dis       Date:  2014-12-13       Impact factor: 4.982

Review 3.  Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?

Authors:  Claire Horgan; Simon A Jones; Brian W Bigger; Robert Wynn
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

4.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

5.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.